Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 19/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376387 | 0.85 | CYP11B1 (0.38) | EIF2AK4DYRK1ADYRK2 | |
| SCHEMBL21194300 | 0.79 | GABRA1 (0.55) | EIF2AK4 | |
| SCHEMBL21194630 | 0.76 | EIF2AK4 (0.59) | EIF2AK4 | |
| SCHEMBL376746 | 0.76 | IRAK4 (0.49) | DYRK1A | |
| SCHEMBL22228873 | 0.74 | EIF2AK4 (0.43) | EIF2AK4DYRK1ADYRK2 | |
| SCHEMBL376287 | 0.73 | PKM (0.54) | DYRK1A | |
| SCHEMBL16748020 | 0.73 | USP7 (0.40) | — | |
| SCHEMBL20455687 | 0.73 | EIF2AK4 (0.52) | EIF2AK4DYRK1ADYRK2 | |
| SCHEMBL376271 | 0.73 | IRAK4 (0.57) | — | |
| SCHEMBL376363 | 0.73 | TRIM33 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | EIF2AK4 233/4885DYRK1A 1255/4885DYRK2 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.